Facts and controversies in systemic treatment of metastatic breast cancer.
about
Liver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin: Case Report and Review of the LiteratureThe Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast CancerCapecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trialA phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanesSalvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review studyIxabepilone plus capecitabine with capecitabine alone for metastatic breast cancer.Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiationAHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.Exclusive and adjuvant radiotherapy in breast cancer patients with synchronous metastases.Positive psychology in cancer care: a story line resistant to evidenceBiobehavioral, immune, and health benefits following recurrence for psychological intervention participants.Sustained complete remission of human epidermal growth factor receptor 2-positive metastatic breast cancer in the liver during long-term trastuzumab (Herceptin) maintenance therapy in a woman: a case report.Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer.Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells.Metastatic breast cancer in a Nigerian tertiary hospital.Treatment Considerations for the Management of Patients With Hormone Receptor-Positive Metastatic Breast Cancer.Breast carcinoma metastasis to the lacrimal gland: Two case reportsAdvances in the management of metastatic breast cancer: options beyond first-line chemotherapy.Lapatinib: the evidence for its therapeutic value in metastatic breast cancer.A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.Down-regulating HIF-1α by lentivirus-mediated shRNA for therapy of triple negative breast cancer.Second-line treatment of postmenopausal women with advanced breast carcinoma.Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer.A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer.The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.Treatment options for breast cancer and bone metastases.Management of advanced breast cancer with the epothilone B analog, ixabepiloneTreatment of the primary tumor in breast cancer patients with synchronous metastases.Vinflunine: review of a new vinca alkaloid and its potential role in oncology.Treatment of metastatic breast cancer: second line and beyond.Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next?A debate on locoregional treatment of the primary tumor in patients presenting with stage IV breast cancer.The role of circulating tumor cells in breast cancer diagnosis and prediction of therapy response.Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer.Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer.Reversine induces cell cycle arrest, polyploidy, and apoptosis in human breast cancer cells.RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.Inhibition of silibinin on migration and adhesion capacity of human highly metastatic breast cancer cell line, MDA-MB-231, by evaluation of β1-integrin and downstream molecules, Cdc42, Raf-1 and D4GDI.
P2860
Q26779880-478DC76F-A1D6-4A58-BC67-0466057222ACQ28085160-832E223D-B5BC-478D-A498-00CE638D044BQ31050387-D65F2B39-3B37-45CC-B631-E0D3CF96EAD1Q33426722-64BDED15-C9B7-456A-877A-D97304A0A6D8Q33506194-E7C55244-CC50-4E8A-B6C5-D6B7229650BAQ33530524-B862429A-9C8B-4126-ACAA-2B32EFB0E6C0Q33634245-7C17BA9A-88DD-4B62-949F-95AD42BE85A3Q33667940-F14F8077-4620-4849-8BF9-AA8EC15264F1Q33749014-BCB9BC6E-791B-4887-B015-6D477FEC8B63Q33807120-B89C128D-F16C-4CAE-90C5-CC5C4BBF80BCQ34022189-0723E452-7791-40D3-A8E6-EB3782859E76Q34419517-FACE6723-95A3-4757-B424-8061208802C7Q34611801-99A897CF-0309-4588-A7EC-514C81ED6252Q34912378-EDD4799D-A1B8-4ED1-83C4-AA67B1D45574Q35171957-A771ED54-BB23-4897-8004-74FFA9891507Q35687540-CEB83BA0-48AB-49D1-AB0F-26F86BA876EDQ35870257-BC05B3AA-650B-4274-8930-AD7A827C3C84Q35872691-C41F5275-E0B1-4447-9F13-9F91EA212114Q35876373-3A27DCE9-1E15-4740-AF55-4C17E28B561DQ36158701-032FB61A-2316-442F-9FF3-7755044B192FQ36213528-EA0A8C19-4C6C-48CE-874D-5F5E69ADEBD2Q36448699-6D0793AF-6D27-4BDD-9E93-56936D3E0F7AQ36613615-2912B070-32FB-424E-9BA0-1E3825A416BDQ37048596-57958285-8855-4106-B185-3B12CFD5D564Q37360204-09A78A48-1872-4D1C-890B-8E192093E9C3Q37378233-AD4954FE-2E54-47A5-ACDB-82415B8BC8C3Q37401841-62585C54-9677-4F40-8746-3B48803DF7E0Q37403186-BF5B82BC-468F-4AC1-B81B-B7ED1775C372Q37763383-4943B944-1B6E-456E-890E-E70414E455EEQ37768280-60013D0C-002E-4283-A7F5-7B400D7B116EQ37802108-D4AA986A-3635-4660-9FA8-E9A49B9B78C3Q37899888-2B308F8F-0123-4969-A1E3-55383D126A76Q37948672-F47AECCB-0AD5-4CE6-BB41-20607B2964DAQ37960916-5466416E-8ED6-47EB-B302-163314A7D105Q38089744-0878C6B9-7468-456F-BFA2-781EC3387F96Q38527929-94E537AD-7800-4310-A20F-A84BE65F71E9Q39185424-3FE2EE5C-9728-40A2-B545-95F36E831BC5Q39290064-8CFD75EE-85F8-4C5C-A810-767B2E28DD1BQ39311633-262777BF-8703-4943-8CFD-3A1B2D594773Q39439840-336E9A06-2AC4-460A-B7F2-B84B29752BA9
P2860
Facts and controversies in systemic treatment of metastatic breast cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Facts and controversies in systemic treatment of metastatic breast cancer.
@ast
Facts and controversies in systemic treatment of metastatic breast cancer.
@en
type
label
Facts and controversies in systemic treatment of metastatic breast cancer.
@ast
Facts and controversies in systemic treatment of metastatic breast cancer.
@en
prefLabel
Facts and controversies in systemic treatment of metastatic breast cancer.
@ast
Facts and controversies in systemic treatment of metastatic breast cancer.
@en
P1433
P1476
Facts and controversies in systemic treatment of metastatic breast cancer.
@en
P2093
Fatima Cardoso
Martine J Piccart
P304
P356
10.1634/THEONCOLOGIST.9-6-617
P577
2004-01-01T00:00:00Z